- Home
- CRMD vs ELVN Comparison
CRMD vs ELVN Comparison
Compare CRMD & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CRMD | ELVN |
|---|---|---|
| Founded | 2006 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 561.8M | 1.8B |
| IPO Year | 2009 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CRMD | ELVN |
|---|---|---|
| Price | $6.45 | $27.78 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 4 |
| Target Price | $14.67 | ★ $41.00 |
| AVG Volume (30 Days) | ★ 1.4M | 606.7K |
| Earning Date | 06-05-2026 | 06-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 780.00 | 3.17 |
| EPS | ★ 2.04 | N/A |
| Revenue | ★ $311,709,000.00 | N/A |
| Revenue This Year | $1.10 | N/A |
| Revenue Next Year | N/A | $40.06 |
| P/E Ratio | $3.14 | ★ N/A |
| Revenue Growth | ★ 617.03 | N/A |
| 52 Week Low | $5.60 | $13.30 |
| 52 Week High | $17.43 | $30.98 |
Technical Indicators
Market Signals| Indicator | CRMD | ELVN |
|---|---|---|
| Relative Strength Index (RSI) | 36.81 | 46.76 |
| Support Level | $6.13 | $18.89 |
| Resistance Level | $7.44 | $29.63 |
| Average True Range (ATR) | 0.30 | 1.59 |
| MACD | 0.01 | -0.25 |
| Stochastic Oscillator | 22.81 | 0.54 |
Price Performance
Historical ComparisonAbout CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.